

Table 3.7

Verified Outcomes (Annualized Percentages)¹ by Age at Diagnosis for CT and OS Participants for Events between January 2000 and December 2020

Data as of: February 19, 2022; Events between January 1, 2000 and December 31, 2020 or January 1, 2000 and September 30, 2010

	Age at Diagnosis							
	50-59	60-64	65-69	70-74	75-79	80-84	85-89	90-105
Cancer and Death Outcomes between 1/1/2000 and 12/31/2020								
Number of participants²	28496	62321	91040	113168	118515	93608	55537	24345
Mean follow-up (months)	30.9	39.5	45.3	48.3	48.5	46.6	42.0	40.6
Breast cancer	359 (0.49%)	1073 (0.52%)	1908 (0.56%)	2605 (0.57%)	2707 (0.57%)	1798 (0.49%)	769 (0.40%)	229 (0.28%)
Invasive breast cancer	281 (0.38%)	862 (0.42%)	1514 (0.44%)	2159 (0.47%)	2306 (0.48%)	1577 (0.43%)	716 (0.37%)	231 (0.28%)
In situ breast cancer	80 (0.11%)	223 (0.11%)	412 (0.12%)	494 (0.11%)	471 (0.10%)	278 (0.08%)	72 (0.04%)	11 (0.01%)
Ovarian cancer	26 (0.04%)	78 (0.04%)	183 (0.05%)	249 (0.05%)	242 (0.05%)	199 (0.05%)	127 (0.07%)	40 (0.05%)
Endometrial cancer ³	32 (0.08%)	144 (0.12%)	294 (0.14%)	370 (0.14%)	356 (0.13%)	246 (0.12%)	97 (0.09%)	31 (0.07%)
Colorectal cancer	35 (0.05%)	155 (0.08%)	337 (0.10%)	546 (0.12%)	657 (0.14%)	616 (0.17%)	402 (0.21%)	199 (0.24%)
Leukemia	6 (0.01%)	48 (0.02%)	136 (0.04%)	202 (0.04%)	262 (0.05%)	243 (0.07%)	182 (0.09%)	89 (0.11%)
Lung cancer	33 (0.04%)	177 (0.09%)	402 (0.12%)	778 (0.17%)	1017 (0.21%)	870 (0.24%)	472 (0.24%)	214 (0.26%)
Non-Hodgkin's lymphoma	18 (0.02%)	75 (0.04%)	198 (0.06%)	357 (0.08%)	416 (0.09%)	380 (0.10%)	255 (0.13%)	104 (0.13%)
Melanoma of the skin	49 (0.07%)	164 (0.08%)	320 (0.09%)	516 (0.11%)	647 (0.14%)	454 (0.12%)	275 (0.14%)	94 (0.11%)
Pancreas cancer	10 (0.01%)	44 (0.02%)	103 (0.03%)	194 (0.04%)	300 (0.06%)	332 (0.09%)	234 (0.12%)	102 (0.12%)
Total cancer	644 (0.88%)	2186 (1.07%)	4251 (1.24%)	6410 (1.41%)	7147 (1.49%)	5577 (1.53%)	2989 (1.54%)	1194 (1.45%)
Total death⁴	221 (0.30%)	999 (0.49%)	2450 (0.71%)	5465 (1.20%)	10581 (2.21%)	15872 (4.36%)	18787 (9.66%)	18992 (23.07%)
Cardiovascular Outcomes between 1/1/2000 and 9/30/2010								
Number of participants²	22435	50703	75664	80683	65949	40705	15580	2664
Mean follow-up (months)	31.1	41.6	41.9	40.6	40.8	38.3	31.0	17.6
CHD ⁵	35 (0.06%)	131 (0.07%)	307 (0.12%)	396 (0.14%)	458 (0.20%)	379 (0.29%)	166 (0.41%)	28 (0.72%)
Clinical MI	25 (0.04%)	97 (0.06%)	231 (0.09%)	298 (0.11%)	326 (0.15%)	248 (0.19%)	95 (0.24%)	11 (0.28%)
CABG/PTCA	48 (0.08%)	178 (0.10%)	396 (0.15%)	479 (0.18%)	465 (0.21%)	289 (0.22%)	58 (0.14%)	0 (0.00%)
Stroke	26 (0.04%)	100 (0.06%)	191 (0.07%)	303 (0.11%)	364 (0.16%)	315 (0.24%)	124 (0.31%)	22 (0.56%)
Total cardiovascular ⁶	157 (0.27%)	493 (0.28%)	981 (0.37%)	1252 (0.46%)	1342 (0.60%)	999 (0.77%)	344 (0.86%)	58 (1.48%)

¹ Annualized percentages calculated as the number with an event in the age interval divided by the total person years of all participants with time in the interval.² Number of participants with any follow-up time in the age interval.³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.⁴ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.⁵ "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the OS or in the WHI Extension Study 2005-2010.⁶ Total cardiovascular disease includes CHD, angina, CABG/PTCA, carotid artery disease, CHF, stroke, PAD and CVD death. Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010.